Authors: Sangni Qian, Shujuan Lin, Xin Xu, Hao Bai, Aibuta Yeerken, Xiaojiang Ying, Zhenjun Li, Xinglin Fei, Jinhua Yang, Mengling Tang, Jianbing Wang, Mingjuan Jin and Kun Chen
Clinical Epigenetics, 05 September 2022
The novel long noncoding RNA MEF2C-AS1 has been identified to be downregulated and have tumor suppressor roles in a number of cancers, as characterized by an inhibition in cell proliferation. In this study, the authors investigated the methylation status of MEF2C-AS1 and its role in colorectal cancer (CRC). The effect of MEF2C-AS1 methylation was analyzed with an in vitro cell proliferation, migration and invasion assay. The Axion BioSystems Exact FL was used to examine cell proliferation by counting the cells 24 h and 48 h after transfection. The results show that overexpression of MEF2C-AS1 was associated with a suppressed cell proliferation in RKO cells. These findings demonstrate the tumor-suppressing role of MEF2C-AS1 in CRC, which may serve as a prognostic biomarker for CRC survival.
